The role of nesfatin and selected molecular factors in various types of endometrial cancer

Markowska, Anna; Szarszewska, Monika; Knapp, Paweł; Gryboś, Anna; Gryboś, Marian; Marszałek, Andrzej; Filas, Violetta; Wójcik‐Krowiranda, Katarzyna; Swornik, Malgorzata; Markowska, Janina

doi:10.5603/gp.2019.0099

Cited by 8 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, there are two types of EC that differ in terms of etiology, biology, and clinical course, i.e., type I EC (endometrioid adenocarcinoma) and type II EC (non-endometrioid adenocarcinoma). The study results demonstrated that in type I EC, nesfatin-1 expression was significantly higher in G1 than G2 and G3 (in total; G1—68.97% compared to G2 and G3—50.4%, p = 0.0487) [ 51 ]. To conclude, the presented results suggest that the expression of NUCB2/NESF-1 may be significant for the prognosis in EC patients.…”

Section: Nucb2—a Predictive/prognostic Biomarker In Cancers?mentioning

confidence: 99%

Nucleobindin-2/Nesfatin-1—A New Cancer Related Molecule?

Kmiecik

Dzięgiel

Podhorska‐Okołów

2021

IJMS

View full text Add to dashboard Cite

Cancer is a heterogeneous disease, and even tumors with similar clinicopathological characteristics show different biology, behavior, and treatment responses. As a result, there is an urgent need to define new prognostic and predictive markers to make treatment options more personalized. According to the latest findings, nucleobindin-2/nesfatin-1 (NUCB2/NESF-1) is an important factor in cancer development and progression. Nucleobindin-2 is a precursor protein of nesfatin-1. As NUCB2 and nesfatin-1 are colocalized in each tissue, their expression is often analyzed together as NUCB2. The metabolic function of NUCB2/NESF-1 is related to food intake, glucose metabolism, and the regulation of immune, cardiovascular and endocrine systems. Recently, it has been demonstrated that high expression of NUCB2/NESF-1 is associated with poor outcomes and promotes cell proliferation, migration, and invasion in, e.g., breast, colon, prostate, endometrial, thyroid, bladder cancers, or glioblastoma. Interestingly, nesfatin-1 is also considered an inhibitor of the proliferation of human adrenocortical carcinoma and ovarian epithelial carcinoma cells. These conflicting results make NUCB2/NESF-1 an interesting target of study in the context of cancer progression. The present review is the first to describe NUCB2/NESF-1 as a new prognostic and predictive marker in cancers.

show abstract

Section: Nucb2—a Predictive/prognostic Biomarker In Cancers?mentioning

confidence: 99%

Nucleobindin-2/Nesfatin-1—A New Cancer Related Molecule?

Kmiecik

Dzięgiel

Podhorska‐Okołów

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Currently, it is known that NUCB2 positively correlates with the Gleason grade in prostate cancer and the Fuhrman grade in renal cancer [ 18 , 38 ]. Interestingly, Markowska et al demonstrated that in type I endometrial cancer, the expression of nesfatin-1 was significantly higher in G1 than in G2 and G3 in total ( p < 0.05) [ 39 ]. Our study is the first research that shows the association of NUCB2 with the histological grade in BC.…”

Section: Discussionmentioning

confidence: 99%

Expression of NUCB2/NESF-1 in Breast Cancer Cells

Kmiecik

Ratajczak‐Wielgomas²,

Grzegrzółka³

et al. 2022

IJMS

View full text Add to dashboard Cite

Recently, the expression of NUCB2/NESF-1 has been linked to tumor development. We report NUCB2/NESF-1 expression and its relation to clinicopathological parameters in breast cancer cells. Immunohistochemical reactions were conducted on 446 cases of invasive ductal carcinoma (IDC) and 36 cases of mastopathy. The expression of NUCB2/NESF-1 was also examined at the mRNA and protein levels in breast cancer cell lines. A statistically significant higher level of NUCB2/NESF-1 in IDC cells was noted compared to that in mastopathy samples. The level of NUCB2 expression in the cytoplasm of IDC cells decreased with the increasing degree of tumor malignancy (G). Higher NUCB2 expression was found in tumors with estrogen receptor (ER)-positive and progesterone receptor (PR)-positive phenotypes compared to that in estrogen-receptor-negative and progesterone-receptor-negative cases. Moreover, a higher expression was shown in ER(+) and PR(+) MCF-7 and T47D cell lines compared to that in triple-negative MDA-MB-468 and normal human breast epithelial cells. The analysis of the five-year survival rate indicated that a positive NUCB2/NESF-1 expression in tumor cells was also associated with longer patient survival. The study results suggest that NUCB2/NESF1 may play an important role in malignant transformation and may be a positive prognostic factor in IDC.

show abstract

“…The polymorphisms [ 177 ] or mutations [ 178 ] of the nesfatin gene, NUCB2, might be associated with the development of obesity. Recently, an increasing number of studies suggest that nesfatin-1 can be a prognostic factor in several types of cancer, like endometrial [ 179 ], gastric [ 180 ], and bladder cancer [ 181 ]. Moreover, NUCB2 may act as a promoter of tumorigenesis and metastasis in breast cancer and renal cell carcinoma [ 182 , 183 ].…”

Section: Nesfatin-1mentioning

confidence: 99%

Melanoma Progression under Obesity: Focus on Adipokines

Olszańska

Pietraszek-Gremplewicz

Nowak

2021

Cancers

View full text Add to dashboard Cite

Obesity is a growing problem in the world and is one of the risk factors of various cancers. Among these cancers is melanoma, which accounts for the majority of skin tumor deaths. Current studies are looking for a correlation between obesity and melanoma. They suspect that a potential cause of its development is connected to the biology of adipokines, active molecules secreted by adipose tissue. Under physiological conditions, adipokines control many processes, including lipid and glucose homeostasis, insulin sensitivity, angiogenesis, and inflammations. However, when there is an increased amount of fat in the body, their secretion is dysregulated. This article reviews the current knowledge of the effect of adipokines on melanoma growth. This work focuses on the molecular pathways by which adipose tissue secreted molecules modify the angiogenesis, migration, invasion, proliferation, and death of melanoma cells. We also discuss the role of these factors as markers of incidence, metastasis, and melanoma patient survival. Understanding the functions of adipokines will lead to knowledge of whether and how obesity promotes melanoma growth. Further studies may contribute to the innovations of therapies and the use of adipokines as predictive and/or prognostic biomarkers.

show abstract

The role of nesfatin and selected molecular factors in various types of endometrial cancer

Cited by 8 publications

References 27 publications

Nucleobindin-2/Nesfatin-1—A New Cancer Related Molecule?

Nucleobindin-2/Nesfatin-1—A New Cancer Related Molecule?

Expression of NUCB2/NESF-1 in Breast Cancer Cells

Melanoma Progression under Obesity: Focus on Adipokines

Contact Info

Product

Resources

About